Nā huahana

wehewehe:
ʻO ka prim-o-glucosylcimifugin ka hopena anti-inflammatory.Hiki ke kāohi ʻia ka ʻōlelo o iNOS a me COX-2 e ka hoʻoponopono ʻana i ka hōʻailona JAK2 / STAT3 transd.

Nā waeʻano pili:
Alanui hōʻailona > > ka palekana a me ka mumū > > nitric oxide synthase
Kahua noiʻi > > ʻeha / ʻaʻa
Nā Huahana Kūlohelohe > > nā mea ʻē aʻe

Pahuhopu:iNOS
COX-2

Haʻawina In Vitro:
ʻO ka prim-o-glucosylglycine (POG) ka mea kiʻekiʻe loa o ka chromone a me kekahi o nā mea hana nui ma Fangfeng (RS).Hoʻokani ka Prim-o-glucosylglycine i kahi hana anti-inflammatory i ka 264.7 macrophages maka ma ke kāohi ʻana i ka transduction hōʻailona JAK2 / STAT3 a me ke kāohi ʻana i ka hōʻike o iNOS a me COX-2.Ua ana ʻia ka cytotoxicity o prim-o-glucoside ma LPS i hoʻāla ʻia i ka maka 264.7 macrophages.E hoʻohana i ka LPS (1 μG / ml) a me ka hoʻonui ʻana i ka nui o ka prim-o-glucosylglycine (15, 50 a me 100 μG / ml) no 24 mau hola, a ua loiloi ʻia ke ola o ka cell e CCK-8 assay.Hoʻohālikelike ʻia me nā cell DMSO mālama ʻia (mana), 24 mau hola a me ka ʻike ʻana i ka 15-100 μ Ma hope o ka g / ml prim-o-glucoside, ʻaʻole i hoʻopilikia nui ʻia ka cell viability.I mea e aʻo ai i ka hopena anti-inflammatory o prim-o-glucosylglycine, inā paha e hiki i ka prim-o-glucosylglycine ke hoʻopili i ka NO synthesis i nānā ʻia i loko o ka LPS i hoʻōla ʻia i ka maka 264.7 cell.E hoʻohana i ka LPS (1 μG / ml) a me nā ʻano ʻokoʻa like ʻole o ka prim-o-glucosylglycine (15, 50 a me 100 μG / ml) no 24 mau hola.ʻAʻole i ana ʻia ka manaʻo i loko o ka moʻomeheu supernatant e Griess reaction.Ua piʻi nui ka manaʻo o ka no i loko o ka moʻomeheu supernatant me ka hoʻolaha ʻana i ka LPS, a ua kāohi nui ka prim-o-glucoside i ka LPS i hoʻoulu ʻole i ka hana ma ke ʻano hilinaʻi [1].
Ma Vivo Study
ʻO ka wai holoi holoi bronchoalveolar (BALF) i hōʻiliʻili ʻia i 7 mau hola ma hope o ka lawelawe ʻana o ka lipopolysaccharide (LPS), a ua ana ʻia ka pae cytokine ma BALF e ELISA.Hoʻohālikelike ʻia me ka pūʻulu hoʻomalu, TNF ma BALF-α， IL-1 β A me IL-6 mau pae i hoʻonui nui ʻia.Eia naʻe, ʻo ka pretreatment me ka prime-o-glucosylglycine (2.5, 5 a i ʻole 10 mg / kg) i hoʻohaʻahaʻa nui ʻia i ka TNF-α， IL-1 β A me IL-6 ma ke ʻano i hilinaʻi ʻia (P <0.05, P <0.05, 0.01). ) [1].

Hoʻokolo Pūnaewele
Ua hoʻohana ʻia ʻo Kit helu helu (CCK-8) e hoʻoholo i ka ʻike cytotoxic o prim-o-glucosylglycine.I ka pōkole, ua mālama ʻia nā pūnaewele maka 264.7 me ka 1 no ka pūnāwai × Ua hoʻopaʻa ʻia ka nui o 104 mau pūnāwai i loko o nā luawai 96 a hoʻomoʻi ʻia i ka pō.A laila hoʻohana i ka 1 μ Cells i hoʻoulu ʻia me ka g / ml LPS a mālama ʻia me nā ʻano ʻokoʻa like ʻole o ka prim-o-glucosylglycine (15, 50 a me 100 μg / mL; Medchem express, Princeton, NJ, USA) a i ʻole ka mālama DMSO.Ma hope o ka hoʻoulu ʻana ma 37 ℃ no 24 mau hola, ua hoʻohui ʻia ka hopena CCK-8 i kēlā me kēia pūnāwai a hoʻomoʻi ʻia no kahi hola ʻē aʻe.Ua ana ʻia ka absorbance ma 450 nm me ka hoʻohana ʻana i kahi mea heluhelu microplate [1].

Hoao Holoholona
ʻiole [1] BALB / C ʻiole kāne, 8 pule, ma kahi o 18 a 20g ke kaumaha.Ua hoʻokaʻawale ʻia nā ʻiole i 5 mau pūʻulu: pūʻulu mana;hui LPS;LPS + prime-o-glucosylglycine (2.5, 5 a i ʻole 10mg / kg paona kino).Hāʻawi ʻia ka Prime-o-glucosylglycine intraperitoneally.Ma hope o 1 hola, hāʻawi ʻia nā ʻiole i loko o ka hui LPS a me ka hui LPS + prime-o-glucosylglycine i 50 mg / L intranasal (i) (200 mg / L) μ LLPs e hoʻoulu ai i ka hōʻeha ʻeha ʻeha.Hāʻawi ʻia nā ʻiole mana i ka 50% intranasal (in) me ka ʻole LPS μ LPBS
[1]

Kuhikuhi:
[1].Zhou J, et al.Hoʻopili ʻo Prim-O-glucosylcimifugin i ka pane ʻana o ka lipopolysaccharide ma ka RAW 264.7 Macrophages.Pharmacogn Mag.2017 Iulai-Sep;13(51):378-384.
[2].ʻO Chen N, et al.Hoʻopiʻi ʻo Prime-O-glucosylcimifugin i ka lipopolysaccharide-induced acute lung injured i ka ʻiole.Int Immunopharmacol.2013 Iun;16(2):139-47.